Login to Your Account

Clinic Roundup

Thursday, September 26, 2013
• Kempharm Inc., of North Liberty, Iowa, disclosed results from a second pivotal clinical study of KP201 (benzhydrocodone hydrochloride and acetaminophen) in preparation for a new drug application, which the company anticipates filing in the second quarter of 2014.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription